Brand name: Duloxetine (AN)
Duloxetine (AN) is a medicine containing the active ingredient(s) duloxetine. On this page you will find out more about Duloxetine (AN), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: duloxetine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Duloxetine (AN) 30 mg enteric capsule, 28
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
Duloxetine is indicated for the treatment of major depressive disorder (MDD).,Duloxetine is indicated for the treatment of generalised anxiety disorder (GAD).
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance |
Blue opaque/White opaque, size 3 hard capsule filled with white to off-white pellets and imprinted with X on cap & 02 on body with black ink
Images are the copyright of the Pharmacy Guild of Australia |
| Dosage Form | Capsule, enteric |
| Route of administration | Oral |
| Medicine schedule |
28: Prescription Only Medicine, or Prescription Animal Remedy
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 25 degrees Celsius |
| Storage conditions | No information available |
| Life time | 2 Years |
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 40 results
Duloxetine GH Capsules - myDr.com.au
Duloxetine GH Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Pharmacor Duloxetine Capsules - myDr.com.au
Pharmacor Duloxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Chemmart Duloxetine Capsules - myDr.com.au
Chemmart Duloxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
APO-Duloxetine Capsules - myDr.com.au
APO-Duloxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Terry White Chemists Duloxetine Capsules - myDr.com.au
Terry White Chemists Duloxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Andepra Capsules - myDr.com.au
Andepra Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Cymbalta Capsules - myDr.com.au
Cymbalta Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Tixol Capsules - myDr.com.au
Tixol Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Dytrex Capsules - myDr.com.au
Dytrex Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Treatment of fibromyalgia | Australian Prescriber
Find out what approaches work best for patients with fibromyalgia.
Read more on Australian Prescriber website
Found 12 results
Duloxetine versus other antidepressive agents for depression | Cochrane
Although pharmacological and psychological interventions are both effective for major depression, antidepressant drugs remain the mainstay of treatment in moderate to severe major depression. During the last 20 years, newer compounds (such as selective serotonin reuptake inhibitors and dual action agents such as serotonin noradrenalin reuptake inhibitors) have progressively become the most commonly prescribed antidepressants. Duloxetine hydrochloride, one of the most recent antidepressants introduced in the market, is a selective serotonin noradrenergic reuptake inhibitor for oral administration. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of duloxetine in comparison with all other antidepressants in the acute-phase treatment of major depression. Sixteen randomised controlled trials (5735 participants) were included. Duloxetine was not more effective than some other new antidepressant agents in the acute-phase treatment of major depression, and it was less well tolerated than escitalopram and venlafaxine as more patients allocated to duloxetine withdrew treatment before study end. However, due to the limited number of studies per comparison these results should be interpreted with caution.
Read more on Cochrane (Australasian Centre) website
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Cochrane
Read more on Cochrane (Australasian Centre) website
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia | Cochrane
Read more on Cochrane (Australasian Centre) website
Second-generation antipsychotic drugs for major depressive disorder | Cochrane
This review found 28 studies on five second-generation antipsychotic drugs (amisulpride, aripiprazole, olanzapine, quetiapine and risperidone) comparing the effects of the drugs alone or adding them or placebo to antidepressants for major depressive disorder and dysthymia. There is evidence that amisulpride might lead to symptom reduction in dysthymia, while no important differences were seen for major depression. There is limited evidence that aripiprazole leads to symptom reduction when added to antidepressants. Olanzapine had no beneficial effects for treatment of depression when compared to antidepressants or compared to placebo but there was limited evidence for the benefits of olanzapine as additional treatment. Data on quetiapine indicated beneficial effects for quetiapine alone or as additional treatment when compared to placebo; data on quetiapine versus duloxetine did not show beneficial effects in terms of symptom reduction for either group, but quetiapine treatment was less well tolerated. The data, however, are very limited. Slight benefits of risperidone as additional treatment, in terms of symptom reduction, are also based on a rather small number of randomised participants. Generally, treatment with second-generation antipsychotic drugs was associated with worse tolerability, mainly due to sedation, weight gain or laboratory values such as prolactin increase.
Read more on Cochrane (Australasian Centre) website
Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women | Cochrane
Read more on Cochrane (Australasian Centre) website
Nortriptyline for neuropathic pain in adults | Cochrane
Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from damaged tissue (for example, a fall, or cut, or arthritic knee). Neuropathic pain is treated by different medicines to those used for pain from damaged tissue. Medicines such as paracetamol or ibuprofen are not usually effective in neuropathic pain, while medicines that are sometimes used to treat depression or epilepsy can be very effective in some people with neuropathic pain.
Read more on Cochrane (Australasian Centre) website
Treatment of fibromyalgia | Australian Prescriber
Find out what approaches work best for patients with fibromyalgia.
Read more on Australian Prescriber website
Managing osteoarthritis | Issue 4 | Volume 38 | Australian Prescriber
Management of osteoarthritis should be based on a combination of non-drug and drug treatments targeted towards prevention, modifying risk and disease...
Read more on Australian Prescriber website
Second-generation antidepressants for winter depression | Cochrane
Seasonal affective disorder (winter depression) is a type of depression that recurs in the autumn and lasts until the spring. It is similar to regular depression except sufferers are usually very tired and have an increase in their appetite. It is more common in countries with few daylight hours in winter. One of the mainstays of treatment for all depression, including winter depression, are second-generation antidepressants (SGAs) such as selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs). It is not clear how well these drugs work for winter depression and how they compare to each other or to other types of therapy such as light therapy.
Read more on Cochrane (Australasian Centre) website
Switching and stopping antidepressants | Issue 3 | Volume 39 | Australian Prescriber
Switching people from one antidepressant to another is commonly needed but can cause drug withdrawal symptoms, drug interactions and relapse in depression....
Read more on Australian Prescriber website
